LinkedIn Profile

Access BiondVax Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:bvxv 725313 Aug 11th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 10th, 2021 10:24PM Aug 10th, 2021 10:24PM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 10th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 10th, 2021 09:57AM Aug 10th, 2021 09:57AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 9th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 9th, 2021 08:31AM Aug 9th, 2021 08:31AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 8th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 8th, 2021 05:50PM Aug 8th, 2021 05:50PM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 7th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 6th, 2021 10:19PM Aug 7th, 2021 04:41PM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 6th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 22.00 Open Biotechnology Aug 6th, 2021 09:02AM Aug 6th, 2021 09:02AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 5th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 21.00 Open Biotechnology Aug 4th, 2021 11:53PM Aug 5th, 2021 11:54AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 4th, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 21.00 Open Biotechnology Aug 4th, 2021 08:50AM Aug 4th, 2021 08:50AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 3rd, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 21.00 Open Biotechnology Aug 3rd, 2021 08:00AM Aug 3rd, 2021 08:00AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000
nasdaq:bvxv 725313 Aug 2nd, 2021 12:00AM BiondVax Pharmaceuticals Ltd. 1.5K 21.00 Open Biotechnology Aug 2nd, 2021 09:58AM Aug 2nd, 2021 09:58AM BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials of M-001, statistically significant immune responses were safely provoked to the vaccine candidate’s epitopes and to a broad range of flu strains. In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The company is now exploring several alternatives to maximize value for shareholders. Open Universal Flu Vaccine, Influenza, Flu Vaccine, BiondVax, Vaccines, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq Open Jerusalem BioPark, Hadassah Ein Kerem Campus Jerusalem Jerusalem IL 00000

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.